Low-Dose Atropine for Treatment of Myopia
Public ClinicalTrials.gov record NCT03334253. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Low-Dose Atropine for Treatment of Myopia (Myopia Treatment Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study Objectives The objectives for this randomized trial are: 1. To determine the efficacy of daily low-dose atropine (0.01%) for slowing myopia progression over a two-year treatment period in children aged 5 to less than 13 years (Primary Outcome On-Treatment). 2. To determine the efficacy of atropine treatment on myopia progression 6 months following cessation of low-dose atropine treatment (Secondary Outcome Off-Treatment). Synopsis of Study Design The current study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. After a run-in phase during which all participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off treatment.
Study identification
- NCT ID
- NCT03334253
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 5 Years to 12 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2018
- Primary completion
- Apr 14, 2022
- Completion
- Sep 11, 2022
- Last update posted
- Jul 30, 2026
2018 – 2022
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| The Emory Eye Center Dept of Ophthalmology | Atlanta | Georgia | 30322 | — |
| St Luke's Hospital | Boise | Idaho | 83702 | — |
| Illinois College of Optometry | Chicago | Illinois | 60616 | — |
| Ticho Eye Associates | Chicago Ridge | Illinois | 60415 | — |
| Boston Children's Hospital Waltham | Boston | Massachusetts | 02453 | — |
| Pediatric Ophthalmology Associates, Inc. | Columbus | Ohio | 43205 | — |
| Eye Care Associates, Inc. | Poland | Ohio | 44514 | — |
| Dean A. McGee Eye Institute, University of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| Casey Eye Institute | Portland | Oregon | 97239 | — |
| Vanderbilt University Medical Center - Vanderbilt Eye Institute | Nashville | Tennessee | 37232 | — |
| University of Houston College of Optometry | Houston | Texas | 77204 | — |
| Rocky Mountain Eye Care Associates | Salt Lake City | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03334253, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03334253 live on ClinicalTrials.gov.